Media Thread, page-12791

I think it’s most likely the MAST trial has an incorrect study completion date as there are secondary measures which will be collected for up to two years after first dose.

@Kluck study completion is when all measures of the study have been finalised rather than just the primary measure. i.e. in a phase 1 trial, a primary measure might be safety and a secondary measure might be progression free survival. So, a primary completion report can be done to progress the drug to a phase 2 while they continue to gather efficacy data. The first HER-Vaxx phase 2 is a good example… we all thought the trial was completed but they continued to gather secondary measure data which resulted in extending the trial completion date and we will highly likely see an updated version of the HER-Vaxx results, probably with extended PFS and OSS, in the next few months.